CXCL13 and B-cell activating factor as putative biomarkers in systemic sclerosis

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 723-725

  Wutte, N ^a   Kovacs, G ^a   Berghold, A ^a   Reiter, H ^a   Aberer, W ^a   Aberer, E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CXCL13 CHEMOKINE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6;

BLOOD DONOR; CALCINOSIS; CLINICAL FEATURE; ERYTHROCYTE SEDIMENTATION RATE; FINGER ULCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

ADULT; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; CHEMOKINE CXCL13; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 84883432303     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12411     Document Type: Letter

References (10)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Matsushita T, Hasegawa M, Yanaba K, et al,. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signalling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
3. Matsushita T, Fujimoto M, Hasegawa M, et al,. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007; 34: 2056-62.
4. Youinou P, Pers JO,. The late news on baff in autoimmune diseases. Autoimmun Rev 2010; 9: 804-6.
5. Ansel KM, Ngo VN, Hyman PL, et al,. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406: 309-14.
6. Legler DF, Loetscher M, Roos RS, et al,. B cell attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998; 187: 655-60.
7. Wutte N, Berghold A, Krainberger I, Aberer E,. Serum CXCL13 chemokine is not a marker for active Lyme borreliosis. Acta Derm Venereol 2011; 91: 724-5.
8. Ishikawa S,. Aberrant high expression of B lymphocyte chemoattractant (BLC/CXCL13) in a murine model for SLE. Tanpakushitsu Kakusan Koso 2002; 47: 2369-74.
9. LeRoy EC, Medsger TA Jr,. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
10. Wutte N, Berghold A, Löffler S, et al,. CXCL13 chemokine in pediatric and adult neuroborreliosis. Acta Neurol Scand 2011; 124: 321-8.